Abstract
Composite endpoint has been used frequently as a primary endpoint in clinical trials. However, there are some misconceptions on the use of composite endpoints. This paper identifies these misconceptions and discusses how to avoid them.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sankoh, A.J., Li, H., D’Agostino, R.B. Use of composite endpoints in clinical trials. Statist. Med. 2014, 33 4709–4714.
Pfeffer, M.A., Claggett, B., Diaz, R., et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015; 373:2247-2257.
EMA. Points to consider on multiplicity issues in clinical trials. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003640.pdf.
FDA. Clinical studies section of labeling for human prescription drug and biological products - content and format. http://www.fda.gov/RegulatoryInformation/Guidances/ucm127509.htm.
Lubsen, J. and Kirwan, B. (2002). Combined endpoints: can we use them? Statist. Med. 2002; 21:2959–2970.
Dormandy, J. A., Charbonnel, B., Eckland, D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366, 1279-1289.
The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357, No. 9266, p1385–1390.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this paper
Cite this paper
Li, J.(., Xu, J. (2016). Some Misconceptions on the Use of Composite Endpoints. In: Lin, J., Wang, B., Hu, X., Chen, K., Liu, R. (eds) Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Analytics. ICSA Book Series in Statistics. Springer, Cham. https://doi.org/10.1007/978-3-319-42568-9_15
Download citation
DOI: https://doi.org/10.1007/978-3-319-42568-9_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42567-2
Online ISBN: 978-3-319-42568-9
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)